Related Experiment Video
Updated: Jul 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023
Hanlu Jia1, Yan Zhao1, Yuan Guan1
1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
What Is Already Known About This Topic?:
Antiretroviral therapy (ART) is the cornerstone of HIV care. In China, efavirenz-based regimens have long been widely used as first-line treatment, while integrase strand transfer inhibitor (INSTI)-based regimens are increasingly available. However, nationwide evidence on virologic outcomes across common first-line regimens remains limited.
What Is Added By This Report?:
This nationwide cohort study found higher viral suppression with EFV 400 mg-based regimens compared with EFV 600 mg- and LPV/r-based regimens, while INSTI-based regimens showed the highest suppression overall.
What Are The Implications For Public Health Practice?:
Findings support expanded use of INSTI-based regimens and consideration of EFV 400 mg-based regimens during ongoing optimization of first-line ART in China.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Retroviruses
Viral Hepatitis I: Introduction
Inhibitors of Virion Maturation and Assembly
Subviral Agents

